(Q38128352)

29 August 2017

title

Safety evaluation of trabectedin in treatment of soft-tissue sarcomas (English)

1 reference

29 August 2017

Juan Martin-Liberal

1

1 reference

29 August 2017

Ian Judson

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

12 August 2013

1 reference

Expert Opinion on Drug Safety

29 August 2017

published in

1 reference

29 August 2017

volume

12

1 reference

29 August 2017

issue

6

1 reference

29 August 2017

page(s)

905-911

1 reference

Trends in survival for patients with metastatic soft-tissue sarcoma

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

New systemic therapy options for advanced sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

A review of trabectedin (ET-743): a unique mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Role of homologous recombination in trabectedin-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.829037

10.1517/14740338.2013.829037

21 January 2018

Identifiers

DOI

1 reference

release_v5ko7flyr5fzlb6eabpf4upolu

29 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v5ko7flyr5fzlb6eabpf4upolu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference